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Cohort profile
ABSTRACT
Purpose The Mollerussa prospective cohort was created 
to study pre-diabetes in a population-based sample 
from the primary care setting in the semirural area of Pla 
d’Urgell in Catalonia (Spain). The aims of the study were to 
assess the prevalence of pre-diabetes in our population, 
the likelihood to develop overt diabetes over time and to 
identify risk factors associated with the progression of the 
condition.
Participants The cohort includes 594 subjects randomly 
selected between March 2011 and July 2014 from our 
primary care population, who were older than 25 years, 
consented to participate and did not have a recorded 
diagnosis of diabetes.
Findings to date At baseline, we performed a clinical 
interview to collect demographic, clinical and lifestyle 
(including a nutritional survey) characteristics; carotid 
ultrasound imaging to assess subclinical cardiovascular 
disease was also performed, and a blood sample was 
collected, with an overall <5% rate of missing data. An 
additional blood draw was performed 12 months after 
initial recruitment to reassess laboratory results in patients 
initially identified as having pre-diabetes, with an 89.6% 
retention rate. Several studies investigating various 
hypotheses are currently ongoing.
Future plans All subjects recruited during the cohort 
creation will be followed long-term through annual 
extraction of data from health records stored in the 
electronic Clinical station in Primary Care database. The 
Mollerussa cohort will thus be a sound population-based 
sample for multiple future research projects to generate 
insights into the epidemiology and natural history of pre-
diabetes in Spain.
InTroducTIon
According to the American Diabetes Asso-
ciation (ADA), diabetes is broadly classified 
into four categories: type 1 diabetes mellitus 
(T1DM), type 2 diabetes mellitus (T2DM), 
gestational diabetes and specific types of 
diabetes due to other causes.1 However, 
there is a group of individuals that, in spite 
of having higher than normal glucose levels, 
do not meet criteria for diabetes, a condition 
referred to as pre-diabetes.
There are different definitions of pre-dia-
betes, but the most common one, the ADA 
criteria, considers one of the following 
instances1: (a) impaired fasting plasma 
glucose (IFG), defined as fasting plasma 
glucose (FPG) between 100 and 125 mg/dL 
(5.6–5.9 mmol/L); or (b) impaired glucose 
tolerance (IGT), defined as a 2-hour plasma 
glucose value after a 75g oral glucose toler-
ance test (OGTT) between 140 and 199 mg/
dL (7.8–11.0 mmol/L); or (c) glycated 
haemoglobin (HbA1c) levels between 5.7% 
and 6.4% (39–46 mmol/mol).
The prevalence of pre-diabetes varies across 
countries and depending on the parameter 
used for the estimations. Based solely on IGT, 
its worldwide prevalence among adults has 
been estimated by the International Diabetes 
Strengths and limitations of this study
 ► The Mollerusssa cohort contains data from subjects 
with pre-diabetes identified in a primary care setting 
that were collected prospectively during 12 months, 
minimising recall bias.
 ► There was a potential selection bias, with higher 
rates for women and middle-aged among enlisted 
subjects than among eligible but not enlisted 
subjects, which will be minimised through a 
weighting process during the analyses.
 ► Subjects will be followed long-term through annual 
extraction of data included in the individuals’ 
electronic medical records, a design that will 
minimise losses to follow-up.
 ► The long-term follow-up will allow the accurate 
estimation of time trends and clinical features 
associated with progression from pre-diabetes to 
overt diabetes
 ► A potential limitation of the long-term follow-up is 
that it will rely on data that may be incomplete or 
inconsistently measured between subjects
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Federation to be 6.7% in 2015, with half of them (50.1%) 
younger than 50 years.2 In England, solely based on 
HbA1c levels, the prevalence was 35.5% among the adult 
population in 20113; in Spain, isolated IFG and isolated 
IGT were present in 3.4% and 2.9%, respectively, and 
combined IFG–IGT in 2.2% of the adult population in 
20104; and in the USA, using the ADA definition (HbA1c 
levels or IFG or IGT) the prevalence was as high as 38% 
in 2012.5
Understanding the epidemiology and natural history of 
pre-diabetes has become a health priority, in particular at 
the primary care setting, because it is a source of avoidable 
morbidity and mortality. First, individuals with IFG and/
or IGT have a clinical phenotype that resembles patients 
with T2DM, as they tend to be older, have a higher body 
mass index (BMI), have more frequent insulin resistance 
and dyslipidaemia and have higher arterial blood pres-
sure (BP) than people with normal glucose tolerance.6 
Second, people with pre-diabetes are at increased risk of 
developing diabetes: according to the ADA, up to 70% of 
them will eventually develop overt diabetes7; the annual 
incidence of progression to diabetes is around 5%–10% 
depending on the population characteristics and the defi-
nition of pre-diabetes; 6%–9% in subjects with isolated 
IFG, 4%–6% in those with isolated IGT, up to 15%–19% 
among those with both IFG and IGT8 9 and subjects with 
HbA1c levels from 5.7% to <6.5% have a 7.5-year predicted 
risk of 43.1% for incident diabetes.10 Finally, individuals 
with pre-diabetes are at increased risk of cardiovascular 
disease (CVD) and premature mortality: a meta-analysis 
found that the risk of CVD is increased regardless of type 
of blood glucose assessment in comparison to subjects 
with normoglycaemia11; and another recent meta-analysis 
found that risks of all-cause and CVD mortality compared 
with normoglycaemic subjects were increased in individ-
uals with pre-diabetes with ADA defined IFG, IGT or both 
criteria combined, although not with isolated IFG.12
Based on epidemiological and clinical evidence, it is 
important from a prediction and prevention perspec-
tive to target segments of the population with metabolic 
and cardiovascular (CV) signatures associated with an 
increased risk of developing diabetes and CVD.1 The 
Mollerussa cohort was designed to identify undiagnosed 
diabetes or pre-diabetes in the adult primary care popu-
lation from a semirural area of Catalonia (Spain), and 
to further obtain extensive epidemiological, clinical 
(including subclinical atherosclerotic disease) and life-
style data. In the following phases, the cohort will be run 
as prospective observational studies involving identified 
at-risk individuals to determine the progress over time 
regarding risk factors, incident diabetes, incidence of CV 
events, rates of hospitalisation and global mortality.
cohorT descrIpTIon
Mollerussa is a prospective observational cohort study 
conducted in Pla d’Urgell, a semirural area of Catalonia 
(Spain), among subjects from the general population 
with healthcare coverage from the Catalan Institute of 
Health (Institut Català de la Salut).
Based on an estimated prevalence of pre-diabetes in the 
area of Lleida of 11% (10%–19%) in 2011,13 we initially 
calculated that we would need a representative sample of 
940 adults considering a 95% CI and a margin of error 
of ±2%. However, literature published after the initiation 
of the recruitment phase, using HbA1c levels and ADA 
criteria, reported pre-diabetes prevalence between 35.5% 
and 38%.3 5 Using this datum, a random sample of 505 
subjects was sufficient to assess an estimated prevalence of 
about 30% with a 95% CI and a margin of error of ±4%.
recruitment
Using the electronic Clinical station in Primary Care 
(eCAP) health records database implemented in all 
primary care centres in Catalonia, a code number was 
given to each registered adult. During the recruitment 
phase, 24 666 registered health records met inclusion 
criteria, namely subjects older than 25 years and attending 
any Primary Healthcare Centre in the same health area 
in Pla d’Urgell (box 1; figure 1); among them, 2226 
random individuals (about 5% of the total number of 
individuals registered at each centre) were contacted 
by telephone (up to three attempts) and invited to 
participate (figure 1). Randomisation was carried out 
using a randomiser programme (SPSS software V.16.0 
for Windows; SPSS), following the principles of simple 
random sampling.
Main exclusion criteria (box 1) included a previous 
diagnosis of diabetes (T1DM, T2DM and any specific 
subtype of diabetes), and subjects on treatment with oral 
antidiabetic drugs to avoid the inclusion of individuals 
with actual diabetes but optimal glycaemic control, or 
even without diabetes but using metformin as treatment 
for other conditions. Based on their willingness to join 
the study and exclusion criteria, a total of 602 subjects 
were recruited and subsequently invited for an appoint-
ment, of whom four withdrew consent and, for four, we 
did not obtain any baseline laboratory data, therefore 
giving a final study population of 594 subjects.
data collection
The research plan included a first phase involving 
two visits to the primary healthcare centre for baseline 
screening, a second phase conducted 12 months after the 
baseline visits and a third phase of long-term follow-up of 
the cohort.
First phase or baseline screening
The following variables were collected/explored by 
trained research staff in the first visit to the subject’s 
primary healthcare centre: (a) Sociodemographic vari-
ables: age; gender; education level according to the 
International Standard Classification of Education14; 
sector of working activity (primary, secondary or manu-
facturing, tertiary or services); self-perceived work 
activity (minimum, light, moderate, heavy); report on 
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physical activity according to the Spanish-validated Inter-
national Physical Activity Questionnaire15; family history 
of hypertension, dyslipidaemia, hypertriglyceridaemia, 
diabetes mellitus and acute myocardial infarction or 
angina pectoris; personal history of hypertension, dyslipi-
daemia, hypertriglyceridaemia, alcohol consumption and 
smoking habit as reported by the patient; and current 
medication. (b) Anthropometric measures and physical 
examination: BP recorded according to the Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure guidelines16; heart 
rate; body weight; waist circumference; and calculation 
of BMI. (c) Nutritional survey: food intake was assessed 
using a Spanish-validated version of the semiquantitative 
Food Frequency Qquestionnaire17; and we estimated the 
degree of adherence to the traditional Mediterranean 
diet through the Mediterranean Diet score.18 (d) Carotid 
ultrasound imaging to measure intima-medial thickness 
and to assess the presence of carotid atherosclerotic 
plaques as previously described.19 Briefly, both carotids 
were examined following a standardised operational 
procedure and the Mannheim consensus,20 consisting of 
a cross-sectional view of the common, bulb and internal 
segments of the carotid arteries to identify atherosclerotic 
plaques (defined as a focal encroachment into the lumen 
of the carotid), and an online average measurement of 
the carotid intima-media thickness (c-IMT) of these three 
areas, with values of c-IMT above 1.5 mm considered as 
plaques.21
In a second appointment, the following laboratory 
measurements were obtained in fasting conditions: 
complete blood count, lipid, liver, kidney and thyroid 
profile. The study of glycaemia included the measure-
ment of FPG and HbA1c. According to the ADA HbA1c 
criteria,1patients were classified into three groups: (1) 
without glucose metabolism disorders (HbA1c <5.7%), 
(2) with pre-diabetes (HbA1c between 5.7% and 6.4%) 
or with undiagnosed diabetes (HbA1c ≥6.5%). When the 
investigator detected a case of undiagnosed diabetes, the 
individual was re-contacted and advised to visit a general 
practitioner at his/her corresponding primary health-
care centre.
The baseline assessment will allow a first estimation 
of the prevalence of pre-diabetes in our population, its 
associated factors, and whether these subjects also have 
a higher prevalence of subclinical carotid atheroscle-
roses (and are therefore at high risk of CVD) compared 
with normoglycaemic subjects. Moreover, it will build 
Box 1 Summary of inclusion and exclusion criteria
Inclusion criteria
Age ≥25 years
Attended a primary health care centre in the area
Exclusion criteria
Patient information about having diabetes provided in the first contact 
or existing ICD-10 code of diabetes (E11, E14 or E13) registered by a 
physician or confirmed based on clinical data:
 ► HbA1c ≥6.5%
 ► IGT: 2-hour plasma glucose in the 75g OGTT ≥200 mg/dL (11.1 
mmol/L)
 ► IFG: FPG ≥126 mg/dL (7 mmol/L)
Specific subtypes of diabetes other than T1DM and T2DM:
 ► Gestational diabetes
 ► Genetic defect of beta-cell action
 ► Genetic defect in insulin action
 ► Diseases of the exocrine pancreas (eg, pancreatitis, 
haemochromatosis, pancreatic cancer, cystic fibrosis)
 ► Endocrinopathies (eg, Cushing’s syndrome, glucagonoma, 
somatostatinoma,  hyperthyroidism, pheochromocytoma, 
acromegaly)
 ► Chemical-induced diabetes
 ► Diabetes secondary to infections
 ► Autoimmune diabetes
Use of oral antidiabetic drugs: metformin, dipeptidyl peptidase-4 
inhibitors, sulfonylureas and glitazones
Presence of cardiovascular disease:
 ► Previous hospitalisation to treat heart disease
 ► Heart failure
 ► Left bundle branch block or second degree atrioventricular block
 ► Aortic stenosis
 ► Systolic BP >180 mm Hg or diastolic BP >105 mm Hg
Cancer treated in the preceding 5 years, except non-melanoma skin 
cancers (basal-cell and squamous-cell carcinoma)
Kidney disease, defined as plasma creatinine ≥1.4 mg/dL in men and 
≥1.3 mg/dL in women or proteinuria >2+
Anaemia, defined as haematocrit <36% in men and <33% in women
Hepatitis, defined as transaminases more than 10 times the upper the 
limit of normal
Gastrointestinal diseases (pancreatitis, irritable bowel disease and 
inflammatory bowel disease)
Recent abdominal surgery
Chronic pulmonary obstructive disease requiring domiciliary oxygen 
therapy
Chronic infectious diseases (eg, HIV, active tuberculosis, HBV and HCV)
Use of systemic glucocorticoids or beta blockers
Major psychiatric disorder with psychotic symptoms
BP, blood pressure; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; 
HBV, hepatitis B virus; HCV, hepatitis C virus; ICD, International Classification 
of Diseases; IFG, impaired fasting plasma glucose; IGT, impaired glucose toler-
ance; OGGT, oral glucose tolerance test; T1DM, type 1 diabetes mellitus; T2DM, 
type 2 diabetes mellitus.
Figure 1 Mollerussa study flow chart. CH, clinical history; 
HbA1c, glycated haemoglobin.
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on previous estimates of the prevalence of undiagnosed 
diabetes in primary healthcare in Catalonia.22
Second phase or short-term follow-up
Twelve months after the baseline visits, subjects initially 
fulfilling pre-diabetes criterion underwent a second visit 
to perform another blood draw to reassess the laboratory 
results. This was based on the ADA recommendation 
to repeat testing in the absence of unequivocal hyper-
glycaemia.1 Based on re-evaluated HbA1c levels, those 
subjects with HbA1c levels between 5.7% and 6.4% 
were confirmed as pre-diabetes; those with a subse-
quent increase from pre-diabetes values at baseline to 
HbA1c ≥6.5% after 12 months were considered as inci-
dent diabetes (and as well re-contacted and advised to visit 
a general practitioner); and those with a further decrease 
from pre-diabetes values at baseline to HbA1c <5.7% after 
12 months as regression to normoglycaemia, although 
they will be followed up to rule out a temporary improve-
ment, and thus a false case of regression to normal mean 
HbA1c values.
The 12-month follow-up will give a real estimation of 
pre-diabetes prevalence, valuable information on the 
1-year probability of progression to diabetes and which 
risk factors were relevant to the further development of 
the disease (eg, metabolic traits and lifestyle).
Third phase or long-term follow-up
In addition to the 12-month follow-up, we also plan to 
follow all subjects enrolled in the Mollerussa cohort annu-
ally through cross-sectional extraction of data stored in 
the primary care electronic medical records of the eCAP 
database.23 This is based on the ADA recommendation 
to follow pre-diabetes in asymptomatic adults yearly.1 We 
will extract data for the following variables: any diagnosis 
of T2DM (International Classification of Disease (ICD-
10) codes E11 or E14)22; time since diagnosis; estimated 
glomerular filtration rate using the Modified Diet in Renal 
Disease formula; standardised HbA1c values, using the 
most recent value of the preceding 12 months; presence 
of CVD, including coronary artery disease (ICD-10 codes 
I20, I21, I22, I23 or I24), stroke (ICD-10 codes I63, I64, 
G45 or G46) and peripheral artery disease (ICD-10 code 
I73.9); risk factors, including BMI (most recent value in 
the last 12 months), cholesterol levels (total, low-density 
lipoproteins or LDL-cholesterol and high-density lipopro-
teins or HDL-cholesterol; most recent value in the last 12 
months), BP (systolic and diastolic mean value in the last 
12 months); and data on prescribed glucose-lowering, 
lipid-lowering, antihypertensive and antithrombotic 
medications. This information will be supplemented with 
data registered in the Conjunto Mínimo Básico de Datos 
de Altas Hospitalarias (Set of Minimum Basic Data Set of 
Hospital Admissions),24 which records all admissions to 
public and private hospitals in the region and contains 
information on diagnostics, procedures and discharge 
reports.
With this additional longitudinal approach, we will 
be able to obtain the patient’s data on progression to 
overt diabetes and/or initiation of antidiabetic treat-
ment over time (if directly related to diabetes). This is 
important because besides the annualised incidence rate 
of progression to diabetes, the time course progression 
of dysglycaemia has not been studied at large. From the 
few available studies, the mode of onset of diabetes in 
subjects with pre-diabetes follows a non-linear pattern, 
with a rapid rather than gradual onset of diabetes over 
a 3-year time.25 Moreover, we will be able to obtain data 
on the incidence of other diabetes-associated chronic 
conditions also present at the pre-diabetes stages, such as 
nephropathy, neuropathy or retinopathy; the incidence 
of macrovascular complications over time; the likelihood 
of initiation of hypoglycaemic agents among progressors; 
rates and cause of hospitalisations; and overall mortality.
This study was approved by the Ethics Committee of 
the Primary Healthcare University Research Institute 
(Institut d'Investigació en Atenció Primària, IDIAP) 
Jordi Gol (P12/043), and all patients signed a written 
informed consent form prior to participation. The study 
was conducted in accordance with the Declaration of 
Helsinki (1964).
FIndIngs To daTe
The Mollerussa study completed its recruitment phase 
between August 2011 and July 2014, and the 12-month 
short-term follow-up in July 2015. The enlisted sample 
(n=602) was different from the eligible but not enlisted 
population (n=784) in terms of gender and age (table 1); 
the enlisted sample had a significantly higher propor-
tion of women (58.6% vs 44.0%; p<0.001), and was older 
(mean age 48.1 years vs 45.7 years; p<0.001).
Demographic characteristics of participants who 
provided a blood sample during the first phase (baseline 
visit) are summarised in table 2.
After the first phase, the rate of missing data was less 
than 5% across variables of interest (table 3), which is far 
below the 20% maximum recommended lost to follow-up 
rate in a cohort study.26 Twelve months after the base-
line screening, we obtained a second blood draw from 
89.6% of subjects found to have altered glycaemia levels 
at baseline (n=193 excluding undiagnosed diabetes), a 
retention rate also indicating acceptable validity of the 
results (table 3; figure 1).
We are currently in the phase of longitudinal follow-up of 
all subjects with subjects identified during the first and second 
phase (figure 1), and developing protocols for the analyses 
to explore hypotheses on different features of the epidemi-
ology and natural history of pre-diabetes in our primary care 
setting. The first paper from the Mollerussa project (now in 
preparation) will describe results derived from the short-term 
follow-up of the cohort, namely the prevalence of pre-diabetes 
and undiagnosed diabetes, the clinical and demographic 
profile of patients with pre-diabetes versus those with normal 
glycaemic levels, a first estimation of the annual incidence of 
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overt diabetes among subjects with pre-diabetes and the meta-
bolic, CV and lifestyle disease-associated conditions.
sTrengThs and lImITaTIons
The main strength of the Mollerussa cohort is that it 
includes adult patients from primary care health centres 
prospectively collected, and the opportunity to follow 
participants in the long term through healthcare elec-
tronic registries, which ensures that it will be of use for 
multiple future research projects. The combined short-
term prospective and long-term longitudinal design has 
both advantages and limitations.
The prospective phase (baseline screening and 
12-month short-term follow-up) prevents recall bias 
because the risk for diabetes was assessed before the 
onset of the disease, and the measurement of events in a 
temporal sequence allows for causes to be distinguished 
from effects. However, we must acknowledge a potential 
selection bias, since we had higher rates of women and 
middle-aged subjects among enlisted people than among 
eligible but not enlisted subjects. The influence of this 
potential bias will be minimised through a weighting 
process on the prevalence estimates, although how this 
original unbalance may impact the results is not clear, 
because IFG and HbA1c detect different categories of 
individuals as being at risk: IFG is substantially more 
common among men, and its prevalence tends to plateau 
Table 1 Age and gender characteristics between subjects eligible but not enlisted and subjects eventually enlisted in the 
Mollerussa cohort
Eligible but not enlisted
Enlisted
(n=602)
Failed to be contacted
(n=448)
Declined to participate
(n=349)
All
(n=797)
Gender (female), n (%) 181 (40.4) 170 (48.7) 351 (44.0) 353 (58.6)*
Age, years, mean (SD) 44 (15.0) 47.9 (16.3) 45.7 (15.7) 48.1 (13.4)†
Age group, years, n (%)
  <40 218 (48.7) 140 (40.1) 358 (44.9) 168 (28.2)
  40–60 160 (35.7) 125 (35.8) 285 (35.8) 315 (52.9)
  >60 70 (15.6) 84 (24.1) 154 (19.3) 113 (19.0)
*χ2 test, p<0.001.
†Kruskal-Wallis non-parametric test, p<0.001.
Table 2 Demographic characteristics of study population 
enrolled in the Mollerussa cohort
Characteristic
Total 
valid N Statistic
Gender, women, n (%) 594 347 (58.4)
Age, years, mean (SD) 594 50.6 (13.3)
Weight, kg, mean (SD) 574 73.1 (14.5)
Waist, cm, mean (SD) 573 94.2 (12.5)
Body mass index, kg/m2, mean 
(SD)
573 26.3 (4.7)
  <25.0, n (%) 236 (41.2)
  25.0–29.9, n (%) 235 (41.0)
  ≥30.0, n (%) 102 (17.8)
Education level, n (%) 575
  Not even primary school 24 (4.2)
  Completed primary school 122 (21.2)
  Secondary/high school 366 (63.7)
  Graduate or higher 63 (11)
Work activity, n (%) 572
  Employed 393 (68.7)
  Unemployed 65 (11.4)
  Disability 12 (2.1)
  Retired 102 (17.8)
Hypertension, n (%) 571 102 (17.9)
Dyslipidaemia, n (%) 571 131 (22.9)
Hypertriglyceridaemia, n (%) 554 22 (4.0)
Smokers, n (%) 594
  Current 152 (25.6)
  Former 148 (24.9)
Alcohol consumption, n (%) 573 286 (49.9)
Table 3 Summary of missing data for variables recorded 
during the first and second phase of the Mollerussa cohort
Variable of interest Missing data, n (%)
First phase (baseline screening); n=594
No clinical interview 17 (2.9)
No nutritional survey 28 (4.7)
No carotid echography 17 (2.9)
No laboratory results 0 (0.0)
No HbA1c measurement 10 (1.7)
No sample for biobank 22 (3.7)
Second phase (12 months follow-up); n=193
No laboratory results 20 (10.4)
HbA1c, glycated haemoglobin.
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in middle age, while the prevalence of pre-diabetes using 
HbA1c increases with age (maximum peak in those aged 
60–74 years) but does not differ by gender.27 28 Finally, 
we did not perform an OGTT among enrolled individ-
uals. Although IGT is more common than IFG in most 
populations, it is more sensitive but slightly less specific 
for identifying people who will develop diabetes.29 Addi-
tionally, the OGTT has low reproducibility and it is 
inconvenient in terms of costs and time consumption.30 
Conversely, HbA1c measurement is cost-effective and 
improves the sensitivity of FPG in the detection of early 
T2DM in high-risk individuals.28 31
On the other hand, the longitudinal, long-term phase 
has the advantage that cohort membership is not depen-
dent on continuing to visit the practice from which the 
members were recruited. While the main strength is that 
this will minimise losses to follow-up, the primary limita-
tion is that it will rely on data that may be incomplete 
or inconsistently measured between subjects. An addi-
tional advantage of this design is that, since the latency 
from pre-diabetes to overt diabetes may be longer than 
the initial 12 months follow-up,25 the long-term follow-up 
will allow a more accurate estimation of the time trends 
(cumulative incidences) and clinical features associated 
with progression to diabetes.
collaboraTIon
The Mollerussa study is open to future joint studies with 
external study groups. Investigators with an interest in 
hypotheses related to pre-diabetes are welcome to contact 
a member of the Institut Universitari d’Investigació en 
Atenció Primària Jordi Gol (IDIAP Jordi Gol) to submit 
a joint study proposal to the Scientific Committee of 
the institution. The group will consider these proposals 
if they are in accordance with the study objectives, and 
do not overlap with other studies already under way. If 
accepted, a formal written agreement will be established 
with the collaborative group.
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